| Document |
Document Title |
|
WO/2021/093377A1 |
In order to improve the device performance of an organic electroluminescent device, particularly the light extraction efficiency, the present application provides an organic electroluminescent device comprising a light extraction layer, ...
|
|
WO/2021/057791A1 |
Provided are a chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further comprising a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be u...
|
|
WO/2021/043185A1 |
Provided herein is a compound as a thyroid hormone β receptor agonist and use thereof. It further relates to a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used in the manufac...
|
|
WO/2021/032648A1 |
Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease.
|
|
WO/2020/251972A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamil...
|
|
WO/2020/249428A1 |
A process for the manufacture of ethyleneamines and ethanolamines, comprising the steps of (i) converting a glycolaldehyde derivative of formula (II), in which R2, R3 are - the same or different -hydrogen, alkyl, such as C1-6-alkyl, or c...
|
|
WO/2020/251974A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamil...
|
|
WO/2020/239105A1 |
The present invention provides a novel method for synthesizing metribuzin, comprising the following steps: 1) adding 6-tert-butyl-4-amino-3-mercapto-1,2,4-triazine-5(4H)-ketone to a certain amount of sulfuric acid in batches, and heating...
|
|
WO/2020/225569A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally s...
|
|
WO/2020/221276A1 |
The present invention relates to a salt of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-dia
mine and a solid form thereof, a method for preparing the solid form and a pharmaceutical composition comprising the solid form, as w...
|
|
WO/2020/206583A1 |
This invention described herein relates to compounds of general formula (I) : (I), in which variable groups are as defined herein, and to their preparation and use. Uses for the compounds and for compositions containing them include trea...
|
|
WO/2020/201460A1 |
A multicomponent crystal (or co-crystal) comprising a first active pharmaceutical ingredient and a second active pharmaceutical ingredient. The multicomponent crystal is formed / sustained by non- covalent interactions between the nitrog...
|
|
WO/2020/169069A1 |
A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds ...
|
|
WO/2020/157189A1 |
The present invention includes name compounds of general formula (I) in which R1, Y, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical composi...
|
|
WO/2020/157194A1 |
The present invention includes name compounds of general formula (I) : (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their...
|
|
WO/2020/144093A1 |
The presently claimed invention relates to a novel, highly efficient and general process for the preparation of the triazine intermediates and their use in the preparation of UV absorbers.
|
|
WO/2020/077123A1 |
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by TH...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/011220A1 |
A heteroaryl derivative represented by general formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative and a use thereof as a therapeutic agent, in particular as an A2a receptor and/or an A2...
|
|
WO/2020/009971A1 |
The present application provides, inter alia, a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, and R6 are as described herein. Methods of making these compounds and m...
|
|
WO/2020/005935A1 |
This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are us...
|
|
WO/2019/243823A1 |
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.
|
|
WO/2019/218797A1 |
Provided is a compound, characterized in being a compound as shown in the following structure: The novel small molecule compound synthesized by the present invention, when applied for external use, can be used for promoting hair regrowth...
|
|
WO/2019/167982A1 |
The present invention pertains to: a saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound having RORγ antagonist activity or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing same;...
|
|
WO/2019/158070A1 |
A heterocyclic compound as an A2A and/or A2B receptor antagonist. Specifically, provided is a compound as represented by the following formula I, wherein each group is as defined in the description. The compound has A2A and/or A2B inhibi...
|
|
WO/2019/141552A1 |
The present invention relates to the triazine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of triazine compounds of f...
|
|
WO/2019/122932A1 |
Compounds of general formula (I): (Formula (I)) wherein R1, R2, X1 and X2 are as defined herein are useful for the treatment of cancer, particularly solid tumours.
|
|
WO/2019/056247A1 |
The present invention belongs to the technical field of pesticides, and in particular relates to a triazinone derivative containing an acylhydrazone structure and a preparation method therefor, and insecticidal and bactericidal uses ther...
|
|
WO/2019/040394A1 |
The present disclosure is directed to non-corrosive cleaning compositions that are useful, e.g., for removing residues (e.g., plasma etch and/or plasma ashing residues) and/or metal oxides from a semiconductor substrate as an intermediat...
|
|
WO/2019/028272A1 |
Disclosed herein are compositions and methods for stabilizing a benzothiazole luciferin analog such as D-luciferin and 6-amino-D-luciferin. The compositions may include the benzothiazole luciferin analog, a thionucleobase compound of for...
|
|
WO/2018/226923A1 |
An antimicrobial compound comprising 1, 3, 5-triazine core substituted with quinoline or imidazolidine-2, 4-dione.
|
|
WO/2018/208123A1 |
The present invention relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1...
|
|
WO/2018/148745A1 |
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, ab...
|
|
WO/2018/130184A1 |
The present invention relates to a 1,2,4-triazine-3-amine derivative, a preparation therefor, and use thereof in medicine. Specifically, the present invention relates to a 1,2,4-triazine-3-amine derivative as represented by general formu...
|
|
WO/2018/120978A1 |
The present invention relates to an organic electroluminescence device containing a 1,2,4-triazine based bipolar main material, comprising: a cathode, an anode, and an organic layer; the original layer is one or more of a hole transport ...
|
|
WO/2018/120979A1 |
The present application relates to a 1,2,4-triazine based bipolar main material and an application thereof. The 1,2,4-triazine based bipolar main material has a compound having the structure of formula (I), wherein R1-R6 represent substi...
|
|
WO/2018/101312A1 |
The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active ingredient for medicines. More specifically, the present invention provides a production m...
|
|
WO/2018/095391A1 |
An organic mixture, an organic composition, an organic electronic component, and a preparation method therefor. The organic mixture comprises two organic compounds H1 and H2, the organic compound H1 being a spiro compound, the organic co...
|
|
WO/2018/087019A1 |
The invention relates to a method for producing amide bonds, particularly peptide bonds, with the aid of new amide coupling reagents containing an anion of formula (I); the invention also relates to these new reagents and to the producti...
|
|
WO/2018/074565A1 |
Provided is a novel compound having a P2X7 receptor inhibitory action, and a pharmaceutical composition having a P2X7 receptor inhibitory action. a compound represented by Formula (I), or a pharmaceutically acceptable salt or the like th...
|
|
WO/2018/071547A1 |
This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.
|
|
WO/2018/060076A1 |
The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmf...
|
|
WO/2018/060071A1 |
The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmf...
|
|
WO/2018/049092A1 |
Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, i...
|
|
WO/2018/030466A1 |
The purpose of the present invention is to provide a heterocyclic compound that can have GCN2-inhibiting activity and is expected to be useful in the prevention and treatment of GCN 2-related diseases and the like, including cancer. Prov...
|
|
WO/2018/015328A1 |
The present invention relates to compounds of formula (I) a compound of formula (1') as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions co...
|
|
WO/2017/204318A1 |
Provided is a novel compound having an antagonism to P2X3 and/or P2X2/3 receptors. A compound represented by formula (I) [wherein: R1 represents an optionally substituted alkyl group, etc.; R2 represents an optionally substituted aromati...
|
|
WO/2017/204316A1 |
The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound represented by formula (I): (wherein, R1 represents a substituted or unsubstituted alkyl or the like, R2 represents a substituted o...
|
|
WO/2017/160569A1 |
The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonist...
|
|
WO/2017/156262A1 |
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs
|
